Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

Charles River Laboratories International, Inc. (NYSE: CRL) and Valence Discovery today announced the formation of a strategic partnership to provide clients access to Valence’s artificial intelligence platform for molecular property prediction, generative chemistry, and multiparameter optimization.

This press release features mul